Post-TAVR Bleeding Unaffected by Valve Type in BRAVO 3 Post-TAVR Bleeding Unaffected by Valve Type in BRAVO 3

Nor did the 30-day risk of cardiac events vary between patients receiving balloon-expandable on non-balloon-expandable valves in the post hoc analysis from the trial.Heartwire from Medscape

Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news